XML 67 R43.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Schedule of Information About Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 Years Ended December 31,
 202220212020
Segment Net Sales   
United States$3,132.6 $2,963.1 $2,516.8 
Europe1,213.7 1,099.6 945.2 
Japan559.3 528.0 448.6 
Rest of World610.7 533.2 451.5 
Total segment net sales$5,516.3 $5,123.9 $4,362.1 
Segment Operating Income  
United States$2,130.9 $2,051.0 $1,727.3 
Europe652.2 569.1 479.3 
Japan376.7 348.0 286.4 
Rest of World247.7 185.2 150.1 
Total segment operating income$3,407.5 $3,153.3 $2,643.1 

The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 Years Ended December 31,
 202220212020
Net Sales Reconciliation   
Segment net sales$5,516.3 $5,123.9 $4,362.1 
Foreign currency(133.9)108.6 24.2 
Consolidated net sales$5,382.4 $5,232.5 $4,386.3 
Pre-tax Income Reconciliation  
Segment operating income$3,407.5 $3,153.3 $2,643.1 
Unallocated amounts:
Corporate items(1,714.1)(1,613.8)(1,358.0)
Special charge(60.7)— — 
Intellectual property litigation expenses, net(15.8)(20.6)(405.4)
Change in fair value of contingent consideration liabilities, net35.8 124.1 (13.6)
Foreign currency95.8 47.3 31.5 
Consolidated operating income1,748.5 1,690.3 897.6 
Non-operating income18.9 11.7 19.1 
Consolidated pre-tax income$1,767.4 $1,702.0 $916.7 
Schedule of Enterprise-Wide Information
Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated financial statements.

 As of or for the Years Ended December 31,
 202220212020
Net Sales by Geographic Area   
United States$3,132.6 $2,963.1 $2,516.8 
Europe1,174.8 1,190.3 973.6 
Japan473.6 528.9 460.1 
Rest of World601.4 550.2 435.8 
$5,382.4 $5,232.5 $4,386.3 
Net Sales by Major Product Area  
Transcatheter Aortic Valve Replacement$3,518.2 $3,422.5 $2,857.3 
Transcatheter Mitral and Tricuspid Therapies116.1 86.0 41.8 
Surgical Structural Heart893.1 889.1 761.8 
Critical Care855.0 834.9 725.4 
$5,382.4 $5,232.5 $4,386.3 
Long-lived Tangible Assets by Geographic Area   
United States$1,188.5 $1,195.8 $1,084.3 
Europe191.8197.9192.7
Japan13.219.720.4
Rest of World331.6335.5311.0
$1,725.1 $1,748.9 $1,608.4